Skip to main content
Vera Therapeutics, Inc. logo

Vera Therapeutics, Inc. — Investor Relations & Filings

Ticker · VERA ISIN · US92337R1014 US Professional, scientific and technical activities
Open in API
Filings indexed 418 across all filing types
Latest filing 2021-05-12 Regulatory Filings
Country US United States of America
Listing US VERA

About Vera Therapeutics, Inc.

https://veratx.com/

Vera Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological and rare diseases. The company's mission is to change the standard of care and improve patients' lives. Its lead product candidate is atacicept, a novel biologic molecule being developed for the treatment of IgA nephropathy (IgAN), a progressive autoimmune kidney disease. Vera Therapeutics aims to advance its pipeline of innovative therapies to address significant unmet medical needs within immunology.

Recent filings

Filing Released Lang Actions
S-1/A
Regulatory Filings Classification · 100% confidence The document is a Form S-1/A Registration Statement Amendment No. 2 filed with the SEC by Vera Therapeutics, Inc. It is a regulatory filing related to the registration of securities for an initial public offering (IPO). The text includes details about the offering, underwriting, risk factors, business overview, and other information typical of an S-1 filing. This is not a financial report like an Annual Report (10-K) or Interim Report (IR), nor is it a presentation, earnings release, or management discussion. It is a registration statement amendment under the Securities Act of 1933, which is a regulatory filing. Therefore, the appropriate classification is Regulatory Filings (RNS). The document length (15,000 characters) and content confirm it is a full filing, not just an announcement or certification.
2021-05-12 English
8-A12B
Regulatory Filings Classification · 100% confidence The document is a Form 8-A filed with the SEC for the registration of certain classes of securities pursuant to Section 12(b) or (g) of the Securities Exchange Act of 1934. It describes the registration of Class A common stock on The Nasdaq Stock Market LLC. The document is a regulatory filing related to securities registration and does not contain financial statements, earnings data, or management discussion. It is not an annual report, earnings release, or any other financial report type. It is a specific regulatory filing for securities registration, which fits best under the category 'Regulatory Filings' (RNS). The document length is short (3256 characters), and it is a formal SEC filing form, confirming the classification as RNS with high confidence.
2021-05-11 English
Regulatory Filings 2021
Regulatory Filings
2021-05-11 English
Regulatory Filings 2021
Regulatory Filings Classification · 95% confidence The document is a letter from the company's legal counsel responding to comments from the SEC staff regarding a Registration Statement on Form S-1 filed by Vera Therapeutics, Inc. The letter addresses specific comments and revisions related to the S-1 filing, which is a registration document for securities offerings. The document is not the registration statement itself but a correspondence related to it. It is short (2989 characters) and serves as a regulatory communication rather than a financial report or presentation. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory communications that do not fit other specific categories.
2021-05-10 English
AMENDMENT NO. 1 TO FORM S-1
Capital/Financing Update Classification · 95% confidence The document is an Amendment No. 1 to Form S-1, which is a registration statement filed with the SEC under the Securities Act of 1933. It is related to an initial public offering (IPO) of Vera Therapeutics, Inc. The text includes details about the offering, underwriting, risk factors, business overview, management, and financial information typical of a registration statement for securities issuance. Form S-1 and its amendments are filings related to capital raising and securities registration, not financial reports or earnings releases. Therefore, this document is best classified as a Capital/Financing Update (CAP). The document length is substantial (15,000 characters), and it is not merely an announcement or certification, so it is not RPA or RNS. Hence, the classification is CAP with high confidence.
2021-05-10 English
Regulatory Filings 2021
Regulatory Filings Classification · 95% confidence The document is a detailed letter response to the SEC regarding a Registration Statement on Form S-1 filed by Vera Therapeutics, Inc. It discusses the preliminary price range for the IPO, valuation methodologies for common stock, stock option grants, and related financial and business developments. The letter is a supplemental response to SEC comments on the registration statement, focusing on valuation and accounting for equity issuances. It is not the registration statement itself, nor is it an earnings release or annual report. It is a regulatory correspondence related to the registration process and SEC review. The document is lengthy (15,000 characters) and contains detailed explanations and data but is fundamentally a regulatory filing responding to SEC comments on a Form S-1 registration statement. Therefore, it fits best under Regulatory Filings (RNS).
2021-05-05 English

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.